Xeris Biopharma Holdings Inc (NASDAQ:XERS) does about 2.25M shares in volume on a normal day but saw 862176 shares change hands in Tuesday trading. The company now has a market cap of 283.71M USD. Its current market price is $2.02, marking no change compared to the previous close of $2.02. The 52 week high reached by this stock is $3.26 whilst the lowest price level in 52 weeks is $1.46.
Xeris Biopharma Holdings Inc (XERS) has a 20-day trading average at $2.12 and the current price is -38.04% off the 52-week high compared with 38.36% distance from its 52-week low. The 50-day simple moving average of the closing price is $2.54 and its 200-day simple moving average is $2.24. If we look at the stock’s price movements over the week, volatility stands at 3.40%, which increases to 5.08% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 34.60 to suggest the stock is neutral.
The consensus objective for the share price is $4.75, suggesting that the stock has a potential upside of 57.47% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on March 28, 2024 when Oppenheimer initiated the stock to “Outperform” and issued a price target of $5. Jefferies initiated its price target at $4.
Xeris Biopharma Holdings Inc (XERS) stock is down -3.35% over the week and -14.04% over the past month. Its price is -14.04% year-to-date and 6.88% over the past year.
XERS’s earnings per share are forecast to grow by 15.60% this year and 42.10% over next year. Expected sales for next quarter are $45.1 million, which analysts say will come at $184.43 million for the current fiscal year and next year at $219.33 million. In addition, estimates put the company’s current quarterly revenue at an average of $41.81 million.
To reach the target analysts have set, the stock logically needs to grow 57.47 percent from here.
Outstanding shares total 138.13M with insiders holding 3.87% of the shares and institutional holders owning 44.82% of the company’s common stock. The company has a return on investment of -28.44% and return on equity of -324.20%. The beta has a value of 1.63. Price to sales ratio is 1.73.
